Oklo’s (NYSE: OKLO) Groves isotope reactor enters final pre-startup review after DOE safety approval

Oklo Inc. (NYSE: OKLO) shares have fallen approximately 22% since the United States Department of Energy (DOE) approved the Documented Safety Analysis for the company’s Groves Isotope Test Reactor in Texas on July 1. The stock closed at US$41.11 on July 17 after touching a new 52-week low of US$39.53, showing that the regulatory milestone has not been enough to halt a wider reassessment of advanced nuclear valuations. Groves has moved into the Department of Energy’s final pre-startup review, but readiness approval, fuel loading and first criticality remain outstanding. Oklo Inc. continues to target criticality during July 2026. The central tension is whether Groves can produce operating evidence quickly enough to strengthen confidence in a pre-revenue company valued at approximately US$7 billion.

Why has Oklo stock fallen sharply despite the Groves reactor safety approval?

Oklo Inc. shares closed at US$52.45 on July 1, the day the Groves Documented Safety Analysis approval was announced. By July 17, the stock had fallen to US$41.11, representing a decline of approximately 21.6%.

The shares dropped about 15.8% over the final five trading sessions and 30.1% over one month. The July 17 intraday low of US$39.53 established a new 52-week floor, while the stock remained nearly 79% below its 52-week high of US$193.84.

Approximately 9.2 million shares traded on July 17, when Oklo Inc. declined 1.41%. The broader Nasdaq Composite Index fell 1.4% during the session, indicating that some of the pressure reflected a wider retreat from technology, artificial intelligence and high-growth equities.

Advanced nuclear companies also experienced a sector-wide selloff during the week. Investors have begun reassessing businesses whose valuations rose rapidly on expectations that artificial intelligence data centres, industrial electrification and United States energy policy would create enormous demand for new nuclear power.

The Groves approval addressed one part of Oklo Inc.’s execution risk, but it did not create revenue, authorize reactor operation or establish commercial project economics. That distinction has become more important as investors shift from rewarding strategic announcements to demanding measurable construction, regulatory and operating progress.

Recent cautious coverage from Truist Securities and Guggenheim Securities has added to the change in sentiment. Their more measured assessments reflect concerns about development timelines, capital deployment and how much future success had already been reflected in the company’s earlier valuation.

The market reaction does not indicate that the Groves approval lacks strategic value. It suggests that one regulatory milestone is no longer enough to offset concerns about operating evidence, commercial timing and the financial demands of developing multiple nuclear projects simultaneously.

What exactly did the Department of Energy approve for Oklo’s Texas isotope reactor?

The United States Department of Energy approved the Documented Safety Analysis for the Groves Isotope Test Reactor on July 1 under its Reactor Pilot Program. The analysis establishes the facility’s final safety basis through an assessment of potential hazards, required safety controls and the operating conditions necessary to support startup.

The approval followed several earlier steps. Oklo Inc. entered into an Other Transaction Agreement with the Department of Energy, secured approval for the project’s Nuclear Safety Design Agreement and completed the Preliminary Documented Safety Analysis stage.

Those approvals allowed the company and the Department of Energy to align on the project’s regulatory framework, design assumptions and preliminary safety controls while construction advanced. The Documented Safety Analysis goes further by defining the safety basis for the completed facility and its planned nuclear operations.

It is a significant approval, but it is not an authorization to begin operating the reactor. Groves must still complete a Department of Energy readiness review. That process is expected to evaluate the facility’s physical condition, operating procedures, equipment, safety systems, personnel preparation, quality controls and emergency arrangements.

The Department of Energy must then issue startup approval before Oklo Inc. can receive nuclear fuel, load the reactor core and begin commissioning. Startup testing would examine whether the reactor and its supporting systems perform as expected before the facility proceeds toward first criticality.

Oklo Inc. initially targeted criticality by July 4 as part of the accelerated Reactor Pilot Program schedule. Administrative and authorization timing pushed the expected milestone beyond that date, and the company now continues to target criticality before the end of July.

Why is first criticality important without being equivalent to commercial operation?

First criticality occurs when a nuclear reactor establishes a controlled and self-sustaining chain reaction. It is a major commissioning milestone because it provides the first operating evidence that the core configuration, control systems and reactor physics function together as intended.

For Groves, achieving criticality would support Oklo Inc.’s argument that an advanced reactor can move from groundbreaking to nuclear operation in less than a year under an accelerated authorization framework. The facility is on privately owned land and has been developed using commercially sourced fuel, equipment and systems, making it more representative of private-sector deployment than a conventional experiment located entirely within a national laboratory.

Criticality would not mean that Groves had entered routine commercial isotope production. The reactor would still need to complete testing, demonstrate stable performance and validate its proposed isotope production pathways.

The company would also need to show that the reactor can produce useful materials at the necessary purity, consistency and scale. Commercial supply would require appropriate processing equipment, handling procedures, transportation arrangements, customer qualification and regulatory permissions covering the resulting isotopes.

The schedule is particularly important because rapid deployment is one of the project’s central strategic claims. Reaching criticality during July would strengthen that claim, while a further delay could intensify questions about whether the accelerated timetable was realistic.

A delay would not automatically indicate a technology failure. Readiness reviews and nuclear startup activities are designed to identify issues before operation, and additional work may be appropriate if safety, documentation or equipment questions arise. However, repeated slippage would weaken the investment narrative that Groves can provide a replicable model for faster advanced nuclear deployment.

Why does Groves matter for United States medical and industrial isotope supply?

Groves is an isotope test reactor rather than an electricity-producing Aurora Powerhouse. The facility is intended to develop operating procedures, test reactor performance and validate production methods for radioisotopes used across medicine, industry, research, space exploration and national security.

Radioisotopes support cancer diagnosis, targeted therapies, medical imaging, semiconductor production, industrial inspection and scientific measurement. Certain isotopes decay rapidly and cannot be stored for long periods, making production continuity and timely transportation critical.

United States supply remains exposed to aging production infrastructure, overseas facilities and a limited number of specialised processors. Disruptions can create shortages because replacement capacity is difficult to activate quickly and medical users cannot always substitute one isotope for another.

Oklo Inc. is building its isotope strategy around several production routes. These include recovering valuable isotopes from existing materials, producing fresh isotopes in dedicated reactors and extracting additional isotopes through future nuclear fuel recycling.

Groves represents the dedicated-reactor component of that strategy. The facility is intended to generate the operating data required to support larger production sites, including a planned multi-reactor isotope foundry in Idaho.

Oklo Inc. also has an Idaho Radioisotopes Laboratory operating through a separate United States Nuclear Regulatory Commission materials licence. That licence permits limited handling, processing, manufacturing and distribution of selected isotopes, but the Idaho laboratory does not currently contain an operating isotope production reactor.

Together, the Texas and Idaho projects could create a development sequence in which Groves validates reactor production while the laboratory builds radiochemical processing and handling experience. The commercial opportunity depends on whether Oklo Inc. can integrate those capabilities into a dependable supply platform.

The company has not disclosed comprehensive Groves production volumes, customer contracts, isotope-specific pricing or expected operating margins. The current value of the project therefore lies primarily in technical validation and regulatory learning rather than near-term revenue.

How does Department of Energy authorization differ from commercial NRC licensing?

The Groves reactor is progressing through the Department of Energy’s Reactor Pilot Program. The programme was established to accelerate advanced reactor testing under federal oversight and create a practical pathway for privately developed projects to reach criticality.

Department of Energy authorization for Groves should not be treated as blanket United States Nuclear Regulatory Commission approval for Oklo Inc.’s future commercial reactors. The two agencies operate under different legal authorities and review different project scopes.

The Groves authorization applies to the test reactor and the activities covered by the Department of Energy agreement. Future commercial isotope reactors outside that framework may require Nuclear Regulatory Commission construction, operating or materials licences, depending on the project structure and activity.

Operating data from Groves could still be strategically valuable in later licensing. Safety-system performance, construction records, commissioning experience, operating procedures and fuel-handling data can provide evidence for future regulatory submissions.

That could reduce uncertainty by replacing some design assumptions with measured results. However, the Nuclear Regulatory Commission would independently evaluate any future application and could require additional information, design changes or safety controls.

The distinction is important for investors because rapid progress through the Department of Energy programme does not automatically shorten every future licensing process. Groves can create a regulatory blueprint, but the commercial value of that blueprint will depend on whether future reviewers accept the relevance of its data.

Can Oklo convert the Atomic Alchemy acquisition into an isotope business?

Oklo Inc. acquired Atomic Alchemy Inc. in February 2025 to add radioisotope expertise to its reactor and fuel-cycle portfolio. The acquisition carried purchase consideration of approximately US$28.4 million, consisting primarily of Oklo Inc. shares.

The company has since integrated the operation into its wider isotope business and referred to the Groves facility under Oklo Isotopes in its July announcement. The current portfolio combines the Texas reactor, the Idaho laboratory, the proposed Idaho isotope foundry and longer-term isotope recovery through fuel recycling.

The strategic logic is that isotope production could provide a commercial route separate from electricity sales. Specialised medical and industrial isotopes can command high values because customers prioritise purity, reliability and delivery security.

A dedicated isotope reactor may also reach commercial relevance faster than a fleet of electricity-generating powerhouses. It requires a smaller individual facility and addresses specialised markets where supply constraints can be acute.

However, the commercial pathway remains unproven. A functioning test reactor does not establish customer demand, production cost, processing yield or pricing power. Oklo Inc. must demonstrate that the isotopes produced meet technical and regulatory specifications and that customers will enter supply agreements at economically attractive prices.

Future isotope foundries would also require additional capital, licences, specialised processing equipment and secure distribution arrangements. The economics could differ substantially between individual isotopes, making a broad market-opportunity estimate less useful than product-specific contracts and production data.

Groves becomes financially important if it shortens the route to those commercial facilities. If it remains primarily a test platform without clear follow-on deployment, its strategic value could be real while its contribution to revenue remains limited.

Does Oklo’s balance sheet provide enough room to reach commercial deployment?

Oklo Inc. reported approximately US$2.54 billion in cash, cash equivalents and marketable debt securities at March 31, 2026. That included US$1.59 billion in cash and cash equivalents and approximately US$943 million in current and non-current marketable debt securities.

The liquidity position increased after the company issued approximately 12.38 million shares through an at-the-market offering during the first quarter. The offering generated approximately US$1.18 billion after costs.

This financing materially reduced near-term liquidity risk while increasing the outstanding share count. Oklo Inc. ended the first quarter with approximately 173.87 million shares outstanding, compared with 160.51 million at the beginning of the year.

The company remains pre-revenue. Oklo Inc. reported a first-quarter net loss of US$33.1 million, compared with US$9.8 million a year earlier, while its operating loss increased to US$51.2 million.

Research and development expenditure rose to US$27 million from US$7.8 million. General and administrative expenses increased to US$24.2 million, partly reflecting higher staffing, professional services and stock-based compensation.

Capital expenditure increased to US$32.8 million from approximately US$332,000 a year earlier. That rise shows that Oklo Inc. is moving from design and planning into physical deployment across its projects.

The balance sheet gives management considerable flexibility, but the company is funding an ambitious portfolio that includes Groves, the Aurora Powerhouse, fuel fabrication, isotope processing and nuclear fuel recycling. Capital requirements will increase as more facilities move into construction.

The financial question is therefore not whether Oklo Inc. has enough cash to reach the next milestone. It is whether management can convert that cash into assets that generate revenue and returns before additional financing becomes necessary.

What evidence could reverse the negative sentiment surrounding Oklo shares?

The first immediate catalyst is Department of Energy startup authorization for Groves. That approval would demonstrate that the project has satisfied the readiness requirements necessary to receive and load nuclear fuel.

Fuel loading would provide tangible evidence that Groves had moved beyond regulatory documentation and conventional construction. First criticality would then become the most visible technical milestone.

A successful July criticality event could improve sentiment by demonstrating schedule execution at a time when investors are questioning whether advanced nuclear developers can translate plans into operating facilities. It would not resolve valuation concerns, but it would replace part of the company’s development narrative with measurable evidence.

The next level of proof would involve reactor performance and isotope production. Oklo Inc. would need to show that Groves can operate safely, validate its intended production pathways and generate data supporting future commercial facilities.

Commercial disclosures would be even more important. Named isotope products, customer qualification, supply agreements, planned capacity and expected revenue timing would allow investors to evaluate the business using more than market-opportunity estimates.

The Department of Energy approval has improved the project’s regulatory position. The share-price decline shows that the market now wants a higher standard of evidence. Startup authorization, fuel loading and criticality are the immediate tests, while validated isotope production and customer commitments will determine whether Groves can change Oklo Inc.’s financial outlook.

What are the key takeaways from Oklo’s Groves approval and share-price decline?

• Oklo Inc. shares have fallen approximately 21.6% since the July 1 Groves safety approval.
• The stock closed at US$41.11 on July 17 after touching a new 52-week low of US$39.53.
• Oklo shares are down approximately 15.8% over five trading sessions and 30.1% over one month.
• The Department of Energy approved the Groves Documented Safety Analysis, establishing the test reactor’s final safety basis.
• The approval does not yet authorize fuel receipt, core loading or reactor operation.
• A Department of Energy readiness review and startup approval remain necessary before commissioning can begin.
• Oklo Inc. continues to target first criticality during July after missing the programme’s original July 4 objective.
• Groves is an isotope test reactor and should not be confused with the electricity-generating Aurora Powerhouse.
• Oklo Inc. held approximately US$2.54 billion in cash and marketable securities at March 31 but remains pre-revenue and loss-making.
• Startup authorization, criticality, isotope validation and commercial customer disclosures are the next measurable tests.